We have located links that may give you full text access.
Representation of Patients with Cardiovascular Disease in Pivotal Cancer Clinical Trials.
Circulation 2019 March 19
Cardiovascular disease (CVD) is increasingly common among new cancer patients, with a reported prevalence near 30% at diagnosis.1,2 Cancer patients with concurrent CVD have poorer outcomes than those without CVD.1-3 Despite the high prevalence of CVD and its prognostic significance, there is limited evidence to guide the care of this increasing population. One possible explanation may be the exclusion of CVD patients from clinical trials.3 In the US, pivotal clinical trials of anticancer drugs are reviewed by the Food and Drug Administration (FDA) for adequate representation and safety prior to approval and release.4 However, whether patients with CVD are well-represented in these important clinical trials is unknown.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app